Top broker says buy CSL stock while trading on 'cheapest multiple in a long time'

Could the CSL share price go higher?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • CSL is a "recession-proof" stock according to one analyst 
  • CSL reported record plasma collections in the first half of 2023 
  • CSL shares are relatively flat on the market today 

CSL Limited (ASX: CSL) has fallen slightly on the stock market in the last month, but could now be the time to pounce?

CSL shares have descended 0.84% since market close on 4 April and are fetching $290.81 a piece at last look. In today's trade, CSL shares are 0.03% in the red. For perspective, the S&P/ASX 200 Index (ASX: XJO) is rising 0.01% today.

Let's take a look at the outlook for CSL stock going forward.

Two happy scientists analysing test results in a lab

Image source: Getty Images

What's ahead?

CSL is a global biotechnology company that operates a huge plasma collection network along with developing a range of life-saving therapies and vaccines.

CSL is one of multiple "recession-proof" shares according to Airlie Funds Management head of Australian equities Matt Williams.

Williams noted CSL's collection costs are falling and could go down even more. In quotes provided to The Australian, Williams said:

During Covid, the cost of collecting plasma went up significantly. Those costs are
now reducing and in fact, a recession should actually lead to lower collection costs
because they won't have to pay their blood donors as much.

CSL is absolutely in that basket of recession-proof stocks. It's trading on a similar
multiple to Woolworths but it's actually the cheapest multiple I've seen it for a long
time.

CSL reported a net profit of US$1.62 billion in the first half of the 2023 financial year. The company noted plasma collections were at record levels.

Meanwhile, the team at Morgans has also recently placed an add rating on CSL shares with a $337.92 price target. This implies an upside of about 16% based on CSL's current share price.

Analysts are optimistic plasma collections will lift and more people will take the flu vaccine. Morgans said:

A key portfolio holding and key sector pick, we believe CSL is poised to break-out this year, a COVID exit trade, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares offering good value trading around its long-term forward multiple of ~30x.

CSL share price snapshot

The CSL share price has lifted nearly 9% in the last year.

CSL has a market capitalisation of about $140 billion based on the current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Married elderly man and woman in love spending time together on bench on a phone, symbolising retirement.
Healthcare Shares

Summerset Group delivers Q2 update

Summerset Group saw first-half FY26 sales rise 17%, with resales up 26%.

Read more »

A guy shrugs his shoulders, not sure which is the right decision.
Healthcare Shares

Cochlear shares are flying. Is this just the start?

Up 32% in a month, but can the ASX healthcare stock reach $300 again?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

2 ASX 200 healthcare shares to buy after sector rebounds 23% in a month

The rapid rebound in ASX 200 healthcare shares has caught many investors by surprise.

Read more »

A medical researcher in a white coat holds laboratory equipment and smiles.
Healthcare Shares

2 ASX healthcare shares crashing, now bouncing: buy, hold or sell?

With a 13% to 34% recovery over the past month, do experts believe it's sustainable?

Read more »

Man sleeping with a sleep apnoea mask on.
Broker Notes

Down 22%! 3 reasons to buy the big dip in ResMed shares today

Two leading analysts deliver their verdicts on ResMed’s beaten-down share price.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

ASX healthcare shares have jumped 21% since June. Can the recovery continue?

Can ASX healthcare shares can sustain their recovery?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

After losing half their value, can CSL shares reclaim $275?

A rebound is here, but can it last? Here's what the experts think.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
ASX Share Market News

Healthcare shares lead the ASX 200 again as sector rotation gathers pace

The sector is up 20% in just a month as value investors swoop on blue-chip favourites like CSL.

Read more »